Sernova (TSE:SVA) Stock Price Down 9.1% – Time to Sell?

Sernova Corp. (TSE:SVA) shares were down 9.1% during mid-day trading on Monday . The company traded as low as C$0.10 and last traded at C$0.10. 202,103 shares traded hands during trading, an increase of 69% from the average session volume of 119,336 shares. The stock had previously closed at C$0.11.

Sernova Price Performance

The stock has a market cap of C$39.65 million, a PE ratio of -2.62 and a beta of -0.46. The company has a quick ratio of 18.11, a current ratio of 0.14 and a debt-to-equity ratio of -25.45. The company’s fifty day moving average is C$0.13 and its 200 day moving average is C$0.15.

Sernova (TSE:SVA) last released its quarterly earnings data on Thursday, June 11th. The company reported C$0.01 earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Sernova Corp. will post -0.08 earnings per share for the current fiscal year.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.